117280-04-3

Basic information

• Product Name: 2-amino-3-(2-chlorobenzoyl)-5-(2-(4-isobutylphenyl)ethyl)thiophene
• Synonyms: 2-amino-3-(2-chlorobenzoyl)-5-(2-(4-isobutylphenyl)ethyl)thiophene
• CAS NO: 117280-04-3
• Molecular Weight: 397.969
• Mol File: 117280-04-3.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 2-amino-3-(2-chlorobenzoyl)-5-(2-(4-isobutylphenyl)ethyl)thiophene(CAS DataBase Reference)
• NIST Chemistry Reference: 2-amino-3-(2-chlorobenzoyl)-5-(2-(4-isobutylphenyl)ethyl)thiophene(117280-04-3)
• EPA Substance Registry System: 2-amino-3-(2-chlorobenzoyl)-5-(2-(4-isobutylphenyl)ethyl)thiophene(117280-04-3)

Safety Data

• Hazardous Substances Data: 117280-04-3(Hazardous Substances Data)

Usage

Molecular Structure

Contains a thiophene ring, an amino group, a chlorobenzoyl group, and an isobutylphenyl group.

Biological and Pharmaceutical Properties

Potential medicinal value due to unique structural features.
Can serve as a building block in synthesizing various pharmaceuticals.
Suitable as a target for drug discovery owing to diverse substituent groups.

Applications

Medicinal chemistry
Pharmacology

Potential Research Areas

Exploration of its pharmacological effects
Investigation into its interactions with biological systems
Synthesis of derivatives for enhanced biological activity

Upstream product

• 1041514-31-1 4-(4'-s-butylphenyl)butanoic acid 
• 147598-20-7 4-(4-Isobutyl-phenyl)-butan-1-ol 
• 40018-25-5 2-Chlorobenzoyl acetonitrile 
• 117280-05-4 4-(4-isobutylphenyl)butyraldehyde 
• 73120-67-9 4-(4-isobutylphenyl)-4-oxobutanoic acid 
• 538-93-2 1-phenyl-2-methylpropane 

Downstream Products

• 117279-73-9 4-(2-chlorophenyl)-2-[2-(4-isobutylphenyl)ethyl]-6,9-dimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine 
• 117280-10-1 [5-(2-Chloro-phenyl)-7-[2-(4-isobutyl-phenyl)-ethyl]-1,3-dihydro-thieno[2,3-e][1,4]diazepin-(2Z)-ylidene]-hydrazine 
• 183130-26-9 [5-(2-Chloro-phenyl)-3-ethyl-7-[2-(4-isobutyl-phenyl)-ethyl]-1,3-dihydro-thieno[2,3-e][1,4]diazepin-(2Z)-ylidene]-hydrazine 
• 183130-24-7 2-Amino-N-{3-(2-chloro-benzoyl)-5-[2-(4-isobutyl-phenyl)-ethyl]-thiophen-2-yl}-butyramide 
• 117280-38-3 5-(2-Chloro-phenyl)-7-[2-(4-isobutyl-phenyl)-ethyl]-3-methyl-1,3-dihydro-thieno[2,3-e][1,4]diazepin-2-one 
• 117280-39-4 5-(2-Chloro-phenyl)-7-[2-(4-isobutyl-phenyl)-ethyl]-3-methyl-1,3-dihydro-thieno[2,3-e][1,4]diazepine-2-thione 
• 117280-40-7 [5-(2-Chloro-phenyl)-7-[2-(4-isobutyl-phenyl)-ethyl]-3-methyl-1,3-dihydro-thieno[2,3-e][1,4]diazepin-(2Z)-ylidene]-hydrazine 
• 183130-25-8 5-(2-Chloro-phenyl)-3-ethyl-7-[2-(4-isobutyl-phenyl)-ethyl]-1,3-dihydro-thieno[2,3-e][1,4]diazepine-2-thione 
• 183130-20-3 5-(2-Chloro-phenyl)-3-ethyl-7-[2-(4-isobutyl-phenyl)-ethyl]-1,3-dihydro-thieno[2,3-e][1,4]diazepin-2-one 
• 127113-13-7 (+/-)-2-amino-N-{3-(2-chlorobenzoyl)-5-[2-(4-isobutylphenyl)ethyl]-2-thienyl}propionamide 
• 117280-07-6 2-amino-N-{3-(2-chlorobenzoyl)-5-[2-(4-isobutylphenyl)ethyl]-2-thienyl}acetamide 
• 1027498-92-5 N-{3-(2-Chloro-benzoyl)-5-[2-(4-isobutyl-phenyl)-ethyl]-thiophen-2-yl}-2-iodo-acetamide 
• 117280-09-8 5-(2-chlorophenyl)-7-[2-(4-isobutylphenyl)ethyl]-1,3-dihydro-2H-thieno[2,3-e]-1,4-diazepine-2-thione 
• 117280-08-7 5-(2-chlorophenyl)-7-[2-(4-isobutylphenyl)ethyl-]1,3-dihydro-2H-thieno[2,3-e]-1,4-diazepin-2-one 

Relevant articles and documents

Structural optimization of 4-(2-chlorophenyl)-9-methyl-6H-thieno [3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepines as antagonists for platelet activating factor: Pharmacological contribution of substituents at the 2- and 6-positions of a condensed ring system

A series of 4-(2-chlorophenyl)-9-methyl-6H-thieno [3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine derivatives bearing substituents at the 2- and 6-positions were synthesized, and evaluated in vitro for their inhibitory activity on rabbit platelet aggregation induced by platelet activating factor (PAF) and in vivo for their preventing effect on PAF-induced mortality in mice. The length of alkyl or arylalkyl side chain at the 2-position was responsible for enhancing the affinity for the PAF receptor. The simultaneous substitution at both the 2- and 6-positions resulted in a successful separation of the affinity for the PAF receptor from that for the benzodiazepine (BZ) receptor. Thus, (±)-4-(2-chlorophenyl)-2-[2-(4-isobutylphenyl)ethyl]- 6,9-dimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4] diazepine (Y-24180) was confirmed to be a specific antagonist for the PAF receptor and is currently under clinical trials.